{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:49Z","timestamp":1793835889283,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273287"],"award-info":[{"award-number":["82273287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anaplastic thyroid carcinoma (ATC), an exceptionally aggressive and rare subtype of thyroid cancer, accounts for 1\u20132% of all thyroid cancers yet carries a high mortality rate, with a median survival time of less than one year. Despite significant advancements in in the field of thyroid cancer research, effective therapeutic options for ATC remain notably limited. Recently, targeting deubiquitinating enzymes (DUBs) has emerged as a promising strategy in cancer therapy. In this study, we investigated the roles of two DUBs, USP14 and UCHL5, in the progression of ATC. Our findings revealed that both USP14 and UCHL5 were upregulated at both mRNA and protein levels in ATC. Individually silencing USP14 or UCHL5 significantly inhibited the malignant characteristics of ATC, while the simultaneous knockdown of both DUBs proved to be even more efficacious. Furthermore, b-AP15, a dual-targeting inhibitor acting on USP14 and UCHL5, effectively suppressed tumor growth in nude mice. Mechanistically, USP14 and UCHL5 cooperate to stabilize PKC\u03b1 by concurrently removing K48-linked ubiquitination chains from PKC\u03b1, thereby facilitating the nuclear translocation of transcription factor NF-\u03baB and activating the expression of pro-oncogenic and anti-apoptotic genes, such as C-MYC and BCL-XL. These findings suggest that targeting the USP14\/UCHL5-PKC\u03b1-NF-\u03baB axis may represent a novel therapeutic approach for ATC, offering promising prospects for the development of innovative treatment strategies against this highly lethal disease.<\/jats:p>","DOI":"10.1038\/s41419-025-07890-9","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:13:50Z","timestamp":1755105230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["USP14 and UCHL5 synergistically deubiquitinate PKC\u03b1 and translocate NF-\u03baB to promote the progression of anaplastic thyroid cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Song","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyang","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8376-3690","authenticated-orcid":false,"given":"Xinxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongfu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-029X","authenticated-orcid":false,"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-6418","authenticated-orcid":false,"given":"Minghua","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"7890_CR1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","volume":"401","author":"DW Chen","year":"2023","unstructured":"Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401:1531\u201344.","journal-title":"Lancet"},{"key":"7890_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: A Review. JAMA. 2024;331:425\u201335.","journal-title":"JAMA"},{"key":"7890_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101678","volume":"37","author":"SN Rao","year":"2023","unstructured":"Rao SN, Smallridge RC. Anaplastic thyroid cancer: An update. Best Pr Res Clin Endocrinol Metab. 2023;37:101678.","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"key":"7890_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ecl.2021.11.020","volume":"51","author":"A Maniakas","year":"2022","unstructured":"Maniakas A, Zafereo M, Cabanillas ME. Anaplastic Thyroid Cancer: New Horizons and Challenges. Endocrinol Metab Clin North Am. 2022;51:391\u2013401.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"7890_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188928","volume":"1878","author":"L Zhang","year":"2023","unstructured":"Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities. Biochim Biophys Acta Rev Cancer. 2023;1878:188928.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"7890_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02094-9","volume":"21","author":"J Wang","year":"2023","unstructured":"Wang J, Tan J, Wu B, Wu R, Han Y, Wang C, et al. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy. J Nanobiotechnology. 2023;21:374.","journal-title":"J Nanobiotechnology"},{"key":"7890_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43:1144\u201361.","journal-title":"Arch Pharm Res"},{"key":"7890_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.","journal-title":"Drug Resist Updat"},{"key":"7890_CR9","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"7890_CR10","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.7150\/thno.47137","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Lu L, Deng S, Meng J, Wan C, Huang J, et al. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer. Theranostics. 2020;10:9332\u201347.","journal-title":"Theranostics"},{"key":"7890_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42257-8","volume":"14","author":"K Qin","year":"2023","unstructured":"Qin K, Yu S, Liu Y, Guo R, Guo S, Fei J, et al. USP36 stabilizes nucleolar Snail1 to promote ribosome biogenesis and cancer cell survival upon ribotoxic stress. Nat Commun. 2023;14:6473.","journal-title":"Nat Commun"},{"key":"7890_CR12","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41388-023-02739-x","volume":"42","author":"C Ma","year":"2023","unstructured":"Ma C, Wang D, Tian Z, Gao W, Zang Y, Qian L, et al. USP13 deubiquitinates and stabilizes cyclin D1 to promote gastric cancer cell cycle progression and cell proliferation. Oncogene. 2023;42:2249\u201362.","journal-title":"Oncogene"},{"key":"7890_CR13","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","volume":"17","author":"P D\u2019Arcy","year":"2011","unstructured":"D\u2019Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17:1636\u201340.","journal-title":"Nat Med"},{"key":"7890_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","volume":"147","author":"P D\u2019Arcy","year":"2015","unstructured":"D\u2019Arcy P, Wang X, Linder S. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther. 2015;147:32\u201354.","journal-title":"Pharmacol Ther"},{"key":"7890_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17:57\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"7890_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-023-02805-y","volume":"42","author":"H Gao","year":"2023","unstructured":"Gao H, Yin J, Ji C, Yu X, Xue J, Guan X, et al. Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application. J Exp Clin Cancer Res. 2023;42:225.","journal-title":"J Exp Clin Cancer Res"},{"key":"7890_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33285-x","volume":"13","author":"D Shi","year":"2022","unstructured":"Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13:5644.","journal-title":"Nat Commun"},{"key":"7890_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-022-01040-w","volume":"30","author":"C Zhao","year":"2023","unstructured":"Zhao C, Gong J, Bai Y, Yin T, Zhou M, Pan S, et al. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Cell Death Differ. 2023;30:1\u201315.","journal-title":"Cell Death Differ"},{"key":"7890_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41418-023-01144-x","volume":"30","author":"EL Morgan","year":"2023","unstructured":"Morgan EL, Toni T, Viswanathan R, Robbins Y, Yang X, Cheng H, et al. Inhibition of USP14 promotes TNFalpha-induced cell death in head and neck squamous cell carcinoma (HNSCC). Cell Death Differ. 2023;30:1382\u201396.","journal-title":"Cell Death Differ"},{"key":"7890_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10555-017-9702-0","volume":"36","author":"Y Fang","year":"2017","unstructured":"Fang Y, Shen X. Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications. Cancer Metastasis Rev. 2017;36:669\u201382.","journal-title":"Cancer Metastasis Rev"},{"key":"7890_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z, D\u2019Arcy P, Wang X, Ray A, Tai YT, Hu Y, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014;123:706\u201316.","journal-title":"Blood"},{"key":"7890_CR22","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s10495-019-01561-9","volume":"24","author":"B Sha","year":"2019","unstructured":"Sha B, Chen X, Wu H, Li M, Shi J, Wang L, et al. Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma. Apoptosis. 2019;24:826\u201336.","journal-title":"Apoptosis"},{"key":"7890_CR23","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/s41401-023-01136-0","volume":"44","author":"W Ding","year":"2023","unstructured":"Ding W, Wang JX, Wu JZ, Liu AC, Jiang LL, Zhang HC, et al. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. Acta Pharm Sin. 2023;44:2537\u201348.","journal-title":"Acta Pharm Sin"},{"key":"7890_CR24","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gkab418","volume":"49","author":"C Li","year":"2021","unstructured":"Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021;49:W242\u2013W246.","journal-title":"Nucleic Acids Res"},{"key":"7890_CR25","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb). 2024;5:100625.","journal-title":"Innovation (Camb)"},{"key":"7890_CR26","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u2013D646.","journal-title":"Nucleic Acids Res"},{"key":"7890_CR27","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.4049\/jimmunol.174.3.1686","volume":"174","author":"C Cataisson","year":"2005","unstructured":"Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH. Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-kappa B activity but is independent of TNF alpha signaling in mouse skin in vivo. J Immunol. 2005;174:1686\u201392.","journal-title":"J Immunol"},{"key":"7890_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12020-016-1080-9","volume":"54","author":"S Latteyer","year":"2016","unstructured":"Latteyer S, Tiedje V, Konig K, Ting S, Heukamp LC, Meder L, et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine. 2016;54:733\u201341.","journal-title":"Endocrine"},{"key":"7890_CR29","doi-asserted-by":"crossref","unstructured":"Stenman A, Yang M, Paulsson JO, Zedenius J, Paulsson K, Juhlin CC. Pan-Genomic Sequencing Reveals Actionable CDKN2A\/2B Deletions and Kataegis in Anaplastic Thyroid Carcinoma. Cancers (Basel) 2021, 13.","DOI":"10.3390\/cancers13246340"},{"key":"7890_CR30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126:1052\u201366.","journal-title":"J Clin Invest"},{"key":"7890_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1038","volume":"12","author":"L Jiang","year":"2022","unstructured":"Jiang L, He Q, Chen X, Liu A, Ding W, Zhang H, et al. Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia. Clin Transl Med. 2022;12:e1038.","journal-title":"Clin Transl Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07890-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07890-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07890-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:01:12Z","timestamp":1757422872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07890-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7890"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07890-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was carried out in compliance with the Declaration of Helsinki, and the research protocol received approval from the Ethics Committee of Zhejiang Provincial People\u2019s Hospital. Written informed consent was obtained from all participants prior to the use of tissue samples for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"617"}}